This randomized controlled trial shows that structured moderate-to-vigorous exercise, alone or combined with liraglutide, ...
GLP-1 RA use is associated with improved survival and lower hospitalization rates in patients with type 2 diabetes receiving cancer therapy.
Most patients receiving a GLP-1 receptor agonist (RA) and a biologic continue co-therapy for over a year with few treatment-related adverse events.
GLP-1 drugs mimic the GLP-1 hormone in the body, which helps to treat type 2 diabetes and obesity. In India, GLP-1 RAs are ...
HealthDay News — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for colorectal ...
FDA requests removal of suicidal ideation warnings from GLP-1 RA labels after meta-analysis shows no increased risk compared with placebo.
Series D1 financing with participation from a syndicate of global healthcare-focused investors, including RTW Investments, SR One Capital ...
Although both sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) ...
GLP-1 receptor agonist (RA) prescribing increased from 0.2 to 6.4 per 1000 deliveries predelivery and from 0.3 to 14.6 per 1000 deliveries postdelivery between 2019 and 2024. Among recipients in 2024, ...
In a reminder of the money still on the table for enticing obesity assets, Corxel Pharmaceuticals has raised $287 million in ...
A more detailed review of data by the FDA showed that GLP-1 drugs do not increase the risk of suicidal ideation or behavior.
This activity is jointly provided by Partners for Advancing Clinical Education and Cardiometabolic Health Congress. Supported by an independent medical educational grant from Abbott Diabetes Care, Inc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results